US-headquartered Fluidigm accelerates its R&D and manufacturing activities in Singapore, through the launch of its new Biomedical Product Development Center. This centre will be responsible for the full development of a Fluidigm BioMark II series of instrumentation.
The BioMark II system will allow Fluidigm to expand its business into the biomarker validation market, which is a rapidly growing market in the life science industry. This strategic development makes Fluidigm the first biotechnology company to expand its portfolio in Singapore, with leading-edge biochip and system R&D capabilities. It also underlines the company's confidence in Singapore's technical competence.
The center's initial research activities will support the development of instrumentation for the BioMark II system. The Singapore research group will undertake 100 percent of the R&D on a new biochip fluorescence reader and biochip loader, specially designed for high-throughput genotyping and protein expression applications.
Fluidigm Singapore will also manufacture the BioMark II system. These new instrumentation will allow the company to tap into the genotyping and protein expression markets, valued at US$350 million and US$300 million respectively. This will help Fluidigm expand further into the research tool market, broaden the reach of its current products and enable the development of future products.
Operations for the Biomedical Product Development Center will commence immediately, with its current R&D team of five. Additional staff will be recruited from Singapore's large pool of manufacturing and research expertise. The R&D center will also be supported by the local precision engineering companies, academic, biomedical and pharmaceuticals research institutions.
Share this: 
Del.icio.us |
Email This | 
Printer Friendly
